Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- BMS to File for Apixaban for Stroke Prevention in Japan, US, and Europe Before Year-end
September 27, 2011
- COPD Treatment NVA237 Filed in Europe by Novartis: Sosei
September 27, 2011
- Novartis Announces New PIII Data for Inhaled Therapy NVA237 at ERS Congress
September 27, 2011
- Daiichi Sankyo Unable to Ship 2.36 million Vials of Flu Vaccine Due to Virus Contamination
September 26, 2011
- OncoTherapy To Receive Milestone Payment following Submission of PI Clinical Trial Certificate
September 26, 2011
- Shanghai Genomics Receives New Drug Certificate for the Treatment of IPF in China
September 26, 2011
- 60% of License Agreements Cancelled Due to Changes in Partners’ Business Strategy
September 26, 2011
- Daiichi Sankyo Announces Delay in Flu Vaccine Shipment Due to Possible Contamination
September 26, 2011
- Ajinomoto Files Suit over Actonel Generic Seeking Suspension of Sales
September 26, 2011
- Trans Genic Files Patent Application for Antibody against Novel Lung Cancer Marker
September 26, 2011
- US FDA Completes Review of Protocol for PIII Trial of Collategene: AnGes MG
September 26, 2011
- Astellas: OAB Treatment Betanis Tablets
September 26, 2011
- Ono/Astellas: Once-Every-Four-Weeks Formulation of Recalbon, Bonoteo
September 26, 2011
- MTPC, Janssen Pharma Launch RA Treatment Simponi
September 26, 2011
- Vibativ Approved in Europe for Treatment of Nosocomial Pneumonia: Astellas
September 26, 2011
- Takeda Aiming to Make Comeback in Diabetes Market
September 25, 2011
- Novartis Grows 7% Driven by New Products: President Mitani
September 22, 2011
- PIII Trial for Brain Function Imaging Agent Starts: Nihon Medi-Physics
September 21, 2011
- Nichi-Iko to Postpone M&A of Nichi-iko Pharma Factory Until June 2012
September 21, 2011
- Kaken President Onuma Targets ¥20 Billion in Operating Profits in 2015
September 21, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…